Moderna Price Prediction 2026-2030: Will MRNA Hold $173 or Retest $154?

Moderna's 1 September 8-K sets a $210.58 conversion price, and the stock closed Monday 21 September 2026 at $172.94 in the cash market and 173.03 on its Phemex perpetual. Our Moderna price prediction runs off those company-set levels, because a 26-bar contract that listed on 27 August 2026 carries no 200-day average and no 52-week range.

What 26 bars forbid is most of the toolkit. No 30-session window exists, no 50/200 cross has ever printed, and the range every quote page shows for MRNA belongs to a cash listing our chart never saw. So we measured the limit with a bootstrap. Resampling the 25 daily returns puts one session's move between 2.44 and 5.09 percent, 95 times out of 100.

What Moderna's 26-Bar Perpetual File Forbids

The file opens at 10:00 UTC on 27 August 2026 and runs 26 daily bars to the anchor. A 200-day average needs 200 of them and a 50-day average needs 50, so neither line has existed at any point in this contract's history. How a moving average is built is arithmetic on a window, and the window is longer than the market.

The same shortfall takes out the 30-session window a stock forecast usually leans on, and it takes out the 50/200 cross, because two lines that were never drawn cannot cross. The 52-week range is worse. It describes a Nasdaq listing, and the contract you can trade is four weeks old.

That last gap is the one that matters, because of what it leaves out.

Moderna's shares closed 18 August 2026 at $62.96 and closed 19 August at $174.38, a one-session gain of 176.97 percent on the Phase 3 readout for its personalised cancer therapy. Our perpetual listed six sessions later. The single event that set the price level is outside every bar we can measure, and each level further down this page comes from a market that opened after the repricing had finished. The anchor close of $172.94 sits 0.8 percent under that 19 August print. A month of trading has gone almost nowhere.

How We Measured Moderna's Volatility Without a 200-Day Average

Method: we resampled the 25 daily returns in the file with replacement, 1,000 draws at each of 40 separate seeds, and read the two-sided 95 percent interval of the resulting standard deviation. The population is those 25 returns and nothing else. No second series feeds it and no model is fitted to it.

The interval runs from 2.44 to 5.09 percent a day. Across the 40 seeds the lower bound moved between 2.29 and 2.58 percent and the upper between 5.01 and 5.20 percent, so the seeds agree and the width of the band is the actual finding. Annualised across 365 daily bars it comes out at 47 to 97 percent. How historical volatility is calculated covers the same arithmetic on a long series, where the interval would be a fraction of this one.

A band that wide should change how you read every number below it. One session at the top of the band moves the 173.03 close by $8.80, which is nearly half the distance down to the $154 level in the headline. Scale the same band to twenty-one weekday sessions and it covers 23 percent in either direction without anyone needing a reason.

Why the 11 Percent Move Needs Its Denominator

The tape prints +11.05 percent for the anchor bar, measured over Sunday 20 September's close of 155.81. Sunday turned over $58,682 against Monday's $652,070, so that denominator is a mark set on nine percent of the next day's flow. Read from Friday 18 September's close of 154.15, the same bar is +12.25 percent. Both are true, and only one of them describes a session you could have traded the underlying in.

Eight of the 26 bars are weekend marks. Their median turnover is $60,419 against $475,496 on the 18 weekday bars, a ratio of about one to eight, and they print while Nasdaq is shut. What a perpetual quotes when Nasdaq is closed sets out the mechanism.

The mark itself holds up, and there's a clean test for that. Our 173.03 close stands 0.05 percent from the $172.94 the cash shares printed on the same session, which is the strongest available evidence that this perpetual tracks the stock and does not drift away from it.

What Moderna's Revenue Did While the Share Price Repriced

Revenue was $19.263 billion in FY2022 and $1.944 billion in FY2025, a fall of 89.9 percent across three fiscal years. The first half of 2026 brought in $534 million against $1.300 billion of research spending, and the six-month net loss came to $2.125 billion. The 10-Q for the June quarter carries all three.

Cash says it with less noise. Cash, equivalents and investments stood at $6.910 billion on 30 June 2026, down 15 percent from $8.135 billion six months earlier. The company then guided year-end 2026 cash to a range of $4.7 to $5.2 billion, and that guidance predates any of the money it raised in September.

Then it raised. The 1 September 8-K reports $2.9573 billion of net proceeds from $3 billion of zero-coupon convertible notes due March 2032, with $328.8 million of it spent on capped calls. A balance-sheet question got an answer, and the revenue question did not.

The 2026 framework filed on 31 July targets up to 10 percent growth on 2025 revenue. Against FY2025's $1.944 billion that caps the year near $2.14 billion, and the first half delivered $534 million of it. Roughly three quarters of the year has to arrive in the second half, with about 55 percent of that in the third quarter on the company's own split. My view is that the second-half number is the real test of any Moderna stock price target, and no filing has dated it.

When Is the Next Moderna Catalyst Date?

Analyst Day on 12 November 2026 is the only dated forward item, and the company published it under Key 2026 Investor and Analyst Event Dates in the second-quarter results it filed on 31 July.

No successor FDA decision date exists. The 10-Q names one goal date, 5 August 2026 for the seasonal flu candidate, and the agency approved that vaccine as mFLUSIVA on 5 August. Nothing has taken its place on any primary page.

What we read: the 1 September 8-K and the June-quarter 10-Q. We read the second-quarter results exhibit and the EDGAR filing index, which carries exactly one 8-K between 5 August and 22 September 2026, and that one covers the notes. We checked the investor events page, whose newest listing is still the 31 July call. The investor days page has nothing newer than Analyst Day 2025. The melanoma readout that moved the stock carried no filing date at all, because the partners said only that they would take the data to regulators.

So a Moderna stock forecast 2027 has one calendar entry to hang on, and that entry is a presentation. If you want a dated catalyst to trade against, this name does not have one.

Where This Moderna Price Prediction Puts MRNA Through 2027

The base case is the one I would defend. Every close in the file lands between $133.40 on 30 August and $173.03 on the anchor, and the bear level is a session the contract traded three days before the anchor. Nothing about that band is a forecast. It is a description of the only market this contract has known.

The two bull levels are different in kind and better for it. Moderna set them, priced them against a $142.77 reference on 27 August 2026, and paid $328.8 million of real cash to buy the upper one. Our Micron forecast through 2030 works the same way on a company with twenty years of bars behind it, which is the comparison worth making. A Moderna price prediction 2026 built from a month of data borrows its credibility from the filing, not from the chart.

What breaks the base case is a close under $130.44. Below it you have no reference at all on this contract, and the next landmark down is the $62.96 the cash shares printed on 18 August 2026. That is a 64 percent hole with nothing in it to lean on.

Why an MRNA Price Prediction 2030 Is a Guess About Oncology

The end of 2030 falls 1,562 days past the 21 September 2026 close, and this contract is 26 days old. Any MRNA price prediction 2030 extrapolates a record that does not exist at that horizon, so no figure belongs here and no model should print one.

What 2030 turns on can be named precisely. Moderna's respiratory franchise is shrinking on its own filings, and the melanoma programme with its partner is the reason the stock repriced in August. So a five-year view is a view on one oncology readout converting into revenue, against a business burning about $1.2 billion every six months while it waits. The convertible notes mature on 1 March 2032, which puts the company's own financing horizon beyond 2030 and tells you how long management thinks this takes.

What MRNA Futures Change About Trading Moderna

MRNA futures run on Phemex as the MRNAUSDT perpetual at up to 20x, with funding every eight hours read from the contract's own interval field of 28,800 seconds. How a perpetual futures contract works covers the settlement mechanism behind that.

At 20x the initial margin is 5 percent of notional and maintenance is 2.5 percent. The bootstrap band puts an ordinary session between 2.44 and 5.09 percent, so the top of that band is your entire initial margin in one close-to-close move, before any gap. Size decides this trade long before direction does, and the 26-bar history gives you almost nothing to size against.

Frequently Asked Questions

What is the Moderna price prediction for 2026?

The band runs from $130.44 at the low to $210.58 at the conversion price, with a base case between $154 and $177. The lowest close in the entire file is $133.40 on 30 August 2026, three sessions into the contract's life.

Does MRNA have a 200-day moving average on Phemex?

No. The contract needs 174 more daily bars to build one, which lands around 14 March 2027 on a calendar-day count. A 50-day average arrives first, around 15 October 2026.

Why did MRNA move 176.97 percent in one session?

Moderna and its partner said the melanoma therapy met both its recurrence-free and distant metastasis-free endpoints in a Phase 3 trial. The next session gave back a chunk of it, closing $133.32 on 20 August.

How much dilution do the convertible notes carry?

They convert into 14,246,100 shares initially and a maximum of 21,012,600 under the make-whole terms. Against the 399 million shares outstanding on 30 June 2026 that is 3.6 percent, or 5.3 percent at the cap.

How much cash does Moderna hold?

Moderna held $6.910 billion of cash and investments on 30 June 2026, before September's raise. The company also paid $950 million in July 2026 to settle the patent litigation it announced in the first quarter.

Bottom Line

A 26-bar chart cannot tell anyone where this stock trades in 2030, and the only two forward prices on this page that somebody signed for are $210.58 and $392.62. Both came out of a bond priced on 27 August 2026, the same day our contract printed its first bar, and six sessions after the trial result that nearly tripled the shares. Everything else here is a range measured off a market that arrived too late to see the thing it is pricing. So $154.04 is the level with a real session underneath it, $173.03 is the level with four weeks of habit underneath it, and a 2.44 to 5.09 percent day settles that argument inside a fortnight.

Disclaimer: This article is for informational purposes only and is not financial advice. Cryptocurrency trading involves substantial risk. Always do your own research before making investment decisions.